Saturday 17 October 2026
Export PLX’s income statement to Excel — free account
Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024. In the quarter to June 2026, revenue grew 27.1%, EPS grew 2,281.0% and free cash flow fell 94.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.62
0.08
−2.96%
Follow PLX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
9.71 | 11.30 | 0.00 | 30.79 |
+8 more quarters Free account |
P/S ratio |
2.31 | 2.27 | 2.68 | 2.85 | |
P/FCF ratio |
24.30 | 13.33 | 0.00 | 0.00 | |
P/Operating CF |
(17.92) | 7.87 | 69.65 | (47.16) | |
P/B ratio |
2.61 | 2.58 | 2.93 | 3.33 | |
Price to Tangible BV |
2.61 | 2.58 | 2.93 | 3.33 | |
EV/Sales |
2.05 | 1.85 | 2.48 | 2.70 | |
EV/EBITDA |
6.64 | 6.64 | 0.00 | 21.44 | |
EV/Operating CF |
16.64 | 9.38 | (10.88) | (16.62) | |
EV/FCF |
21.53 | 10.90 | (9.58) | (14.26) | |
Quick Ratio |
1.84 | 2.00 | 1.50 | 2.00 | |
Current Ratio |
2.94 | 3.15 | 2.51 | 3.03 | |
Net Debt/EBITDA |
(8.15) | (2.40) | 7.25 | (11.73) | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.85 | 0.87 | 0.68 | 0.86 | |
Operating CF/Net income |
(2.75) | 1.20 | (0.37) | (1.58) | |
Capex/Depreciation |
(1.46) | (1.88) | (1.04) | (1.34) | |
Research and Development Expense of Revenue |
21.87% | 16.08% | 61.77% | 25.02% | |
Selling, General and Administrative Expense of Revenue |
15.64% | 9.04% | 38.65% | 16.41% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
2.00% | 1.58% | 8.02% | 3.35% | |
Graham Net Nets |
0.29 | 0.30 | 0.23 | 0.21 | |
Graham Number |
2.20 | 1.91 | 0.00 | 1.04 | |
Earnings Yield |
10.30% | 8.85% | (4.88%) | 3.25% | |
Free Cash Flow Yield |
4.11% | 7.50% | (9.64%) | (6.64%) | |
Revenue per Share |
0.25 | 0.42 | 0.12 | 0.23 | |
Operating CF per Share |
(0.13) | 0.28 | 0.03 | (0.05) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.14) | 0.27 | 0.02 | (0.05) | |
Cash per Share |
0.52 | 0.65 | 0.39 | 0.37 | |
Shareholders Equity per Share |
0.89 | 0.84 | 0.61 | 0.67 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.89 | 0.84 | 0.61 | 0.67 | |
Free Cash Flow |
(10.99) | 21.26 | 1.63 | (4.23) | |
Working Capital |
60.83 | 58.97 | 40.16 | 44.56 | |
Capital Expenditures |
(0.59) | (0.76) | (0.40) | (0.50) | |
Net Current Asset Value |
53.29 | 51.25 | 32.56 | 37.15 | |
EV/EBIT |
7.09 | 7.16 | 0.00 | 26.19 | |
Capex to Sales |
0.03 | 0.02 | 0.04 | 0.03 | |
Price to Operating Income |
8.00 | 8.76 | 0.00 | 27.64 | |
| Other line items | |||||
Average Receivables |
12.97 | 4.60 | 5.87 | 8.31 | |
Average Payables |
26.17 | 24.43 | 24.63 | 21.63 | |
Average Inventory |
26.71 | 24.99 | 23.49 | 19.23 | |
Average Assets |
94.41 | 88.11 | 77.88 | 71.91 | |
Average Common Equity |
60.65 | 56.22 | 45.72 | 42.67 |
Columns are period end dates